Federal investigators probing whether pharmacy firms and doctorsoverbilled for prescription drugs have subpoenaed firms including Abbott, Baxter International, Bayer, Bristol-Myers Squibb, Chiron, Gensia Sicor, Glaxo Wellcome, Henry Schein, Immunex, Novartis, Rhone-Poulenc Rorer, SmithKline Beecham and Schering-Plough.
Most firms did not reply to Barron's queries about the probe, but Immunex, Novartis, R-PR and Schering-Plough said they had received subpoenas and were cooperating. Reuters said investigators had told Barron's that Eli Lilly, Merck & Co and Rugby had provided accurate wholesale prices to state Medicaid programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze